Genscript Biotech Corp
HKEX:1548

Watchlist Manager
Genscript Biotech Corp Logo
Genscript Biotech Corp
HKEX:1548
Watchlist
Price: 11 HKD 4.96% Market Closed
Market Cap: 23.1B HKD
Have any thoughts about
Genscript Biotech Corp?
Write Note

Genscript Biotech Corp
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genscript Biotech Corp
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Genscript Biotech Corp
HKEX:1548
Total Current Liabilities
$494.8m
CAGR 3-Years
6%
CAGR 5-Years
25%
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Total Current Liabilities
ÂĄ13.6B
CAGR 3-Years
10%
CAGR 5-Years
23%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Total Current Liabilities
ÂĄ3.9B
CAGR 3-Years
15%
CAGR 5-Years
22%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Total Current Liabilities
ÂĄ6.8B
CAGR 3-Years
8%
CAGR 5-Years
38%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Total Current Liabilities
ÂĄ5.3B
CAGR 3-Years
46%
CAGR 5-Years
37%
CAGR 10-Years
31%
W
WuXi XDC Cayman Inc
HKEX:2268
Total Current Liabilities
ÂĄ1.3B
CAGR 3-Years
241%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Genscript Biotech Corp
Glance View

Market Cap
23.3B HKD
Industry
Life Sciences Tools & Services

Genscript Biotech Corp. is a holding company, which engages in the manufacture and sale of life sciences research products and services. The company is headquartered in Nanjing, Jiangsu. The company went IPO on 2015-12-30. The firm operates through four segments. Life Sciences Research Services segment includes gene and peptide synthesis, deoxyribonucleic acid (DNA) and primer synthesis, DNA sequencing, customized antibody production, protein expression and the production of stable cell lines. Preclinical Drug Development Services segment includes protein and antibody engineering, the study of in vitro drug and the study of in vivo drug. Life Sciences Research Catalog Products segment provides antibodies, recombinant proteins, equipment for protein isolation and analysis, molecular biology reagents, peptide, biochemicals and stable cell lines. Industrial Synthetic Biology Products segment is engaged in the development and production of industrial enzymes.

Intrinsic Value
32.97 HKD
Undervaluation 67%
Intrinsic Value
Price

See Also

What is Genscript Biotech Corp's Total Current Liabilities?
Total Current Liabilities
494.8m USD

Based on the financial report for Jun 30, 2024, Genscript Biotech Corp's Total Current Liabilities amounts to 494.8m USD.

What is Genscript Biotech Corp's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
25%

Over the last year, the Total Current Liabilities growth was 13%. The average annual Total Current Liabilities growth rates for Genscript Biotech Corp have been 6% over the past three years , 25% over the past five years .

Back to Top